-
公开(公告)号：EP3457851A1
公开(公告)日：2019-03-27
申请号：EP17800190.5
申请日：2017-05-18
-
52.发明授权
公开(公告)号：EP3116591B1
公开(公告)日：2019-02-13
申请号：EP15762093.1
申请日：2015-03-09
-
公开(公告)号：EP2601910B1
公开(公告)日：2018-09-19
申请号：EP13153763.1
申请日：2003-08-15
发明人： Pavcnik, Dusan , Case, Brian C. , Flagle, Jacob A , Garrison, Mike , Hoffa, Andrew K. , Leonard, Raymond B., II , Osborne, Thomas A. , Paul, Ram H., Jr. , Schaeffer, Darin G. , Sisken, Richard B.
CPC分类号： C25F3/24 , A61F2/2418 , A61F2/2439 , A61F2/2475 , A61F2220/0008 , A61F2220/0016 , A61F2230/001 , A61F2230/0023 , A61F2230/0026 , A61F2230/0054 , A61F2230/0058 , A61F2230/0091 , A61F2230/0095
摘要： A valve prosthesis (43), such as an artificial venous valve, having a support frame (11) and leaf structure comprising one or more leaflets (78, 79) in which the outer edge (112) of each leaflet engages the inner circumference of the bodily passageway along a serpentine path urged against the passageway by an expandable frame, while the inner edges move in response to fluid to restrict retrograde flow. Optionally, one or more elements (31, 32) can extend from the support frame/leaf structure to provide centering support and/or protection from the leaflet adhering to the vessel wall. In one embodiment, the centering support structure (164) comprises a second or third expandable frames (31, 32) attached to and extending from the proximal and/or distal ends of main valve structure and support frame. In another embodiment, one or more support elements extend outward from the valve support frame to engage the vessel wall to provide greater longitudinal stability.
-
公开(公告)号：EP2734622B1
公开(公告)日：2018-09-05
申请号：EP12814129.8
申请日：2012-07-19
发明人： ZHU, Yong , WU, Shili , BAO, Jun , CHU, Cong-Qiu
CPC分类号： C07K17/06 , A61K38/00 , A61K47/64 , A61K47/645 , A61L27/3612 , A61L27/3654 , C07K14/4702 , C07K14/4703 , C07K14/4716 , C07K2319/21 , C07K2319/60 , C12N5/0637 , C12N5/0655 , C12N5/0676 , C12N5/0696 , C12N2501/60 , C12N2501/602 , C12N2501/603 , C12N2501/604 , C12N2501/606 , C12N2506/14 , G01N33/5073
摘要： The present inventions are directed to compositions and methods regarding the reprogramming of other cells (such as embryonic stem cells (ESCs), induced pluripotent stem cells (iPSCs), MSCs, fibroblasts, hematopoietic stem cells, endothelian stem cells, adipocytes, chondrocytes, osteoblasts, osteoclasts and endothelial cells) into chondrogenic cells without introducing exogenous genes to the samples. In particular, the present inventions are directed to transducible materials that are capable of transducing into the biological samples but are not genes or causing genetic modifications. The present inventions also are directed to methods of reprogramming the path of biological samples or treating diseases using the tranducible compositions thereof.
-
公开(公告)号：EP3142670B1
公开(公告)日：2018-08-22
申请号：EP15726814.5
申请日：2015-05-15
CPC分类号： A61K31/663 , A61K9/0019 , A61K9/127 , A61K9/5153 , A61K31/675 , A61K45/06 , A61K47/24
摘要： The present invention relates to use of bisphosphonate formulations for the treatment and management of HIV/AIDS. The method of the invention comprises administering a formulation comprising an effective amount of a bisphosphonate that specifically inhibits the activity and/or decreases the number of monocytes and/or macrophages, thereby reducing or eliminating HIV reservoirs. The invention also provides a method of complementing an HIV antiviral therapy, such as the highly active antiretroviral therapy (HAART), with a bisphosphonate formulation to improve clinical outcome.
-
公开(公告)号：EP3360566A1
公开(公告)日：2018-08-15
申请号：EP18162110.3
申请日：2010-11-19
申请人： Oregon Health & Science University , The United States Government Represented by the Department of Veterans Affairs
IPC分类号： A61K38/16 , A61K39/39 , C12N15/867 , C12N15/86 , A61P31/06 , A61K39/04 , A61K38/00 , A61K39/385 , A61K49/00 , G01N33/569 , A61K39/00 , A61K9/00
摘要： Methods for detecting an infection with Mtb in a subject are disclosed. The methods include detecting the presence of CD8 + T cells that specifically recognize an Mtb polypeptide. The methods include in vitro assays for detecting the presence of CD8 + T cells in a biological sample, and in vivo assays that detect a delayed type hypersensitivity reaction. The methods also include detecting Mtb polypeptides and polynucleotides.
-
公开(公告)号：EP3263124A1
公开(公告)日：2018-01-03
申请号：EP17183578.8
申请日：2010-11-19
申请人： Oregon Health & Science University , The United States Government as represented by The Department of Veterans Affairs
IPC分类号： A61K38/16 , A61K39/39 , C12N15/867 , C12N15/86 , A61P31/06 , A61K39/04 , A61K38/00 , A61K39/385 , A61K9/00 , A61K49/00 , G01N33/569 , A61K39/00
CPC分类号： A61K39/04 , A61K9/0021 , A61K38/00 , A61K39/385 , A61K49/00 , A61K49/0006 , A61K2039/53 , G01N33/5695 , G01N2333/35 , G01N2469/10 , G01N2800/26 , Y02A50/466
摘要： Methods for producing an immune response to Mycobacterium tuberculosis (Mtb) are disclosed herein. In several examples, the immune response is a protective immune response. In additional embodiments, methods are disclosed for inhibiting an infection with Mtb, preventing an infection with Mtb, or treating an infection with Mtb. Pharmaceutical compositions for the inhibition, prevention and/or treatment of tuberculosis are also disclosed.
摘要翻译： 本文公开了对结核分枝杆菌（Mtb）产生免疫应答的方法。 在几个例子中，免疫应答是保护性免疫应答。 在另外的实施方案中，公开了用于抑制Mtb感染，预防Mtb感染或治疗Mtb感染的方法。 还公开了用于抑制，预防和/或治疗结核病的药物组合物。
-
58.发明公开
公开(公告)号：EP3200878A1
公开(公告)日：2017-08-09
申请号：EP15847978.2
申请日：2015-10-05
申请人： Los Alamos National Security, LLC , Oregon Health & Science University , Vir Biotechnology, Inc.
发明人： BRUENING, Eric , FRUEH, Klaus , PICKER, Louis , KORBER, Bette T.M. , THEILER, James , MARSHALL, Emily
CPC分类号： A61K39/12 , A61K39/21 , A61K2039/53 , A61K2039/70 , C12N2710/16143 , C12N2740/16034 , C12N2740/16234
摘要： Provided herein are HIV-1 vaccines comprising a carrier and a population episensus antigen determined using the EpiGraph approach. Also provided are HIV-1 vaccines comprising a carrier, a population episensus antigen, and a tailored antigen. Also provided are methods of designing and producing an HIV-1 vaccine for a subject comprising designing vaccine antigens to optimally cover the diversity within a geographic area using an antigen amino acid sequence generated using the EpiGraph approach, and producing said designed vaccine antigen. Also provided are methods of inducing an effector memory T cell response comprising designing the one or more EpiGraph amino acid sequences, producing a vaccine comprising the one or more EpiGraph amino acid sequences and a vector, and administering the vaccine to a subject. Further provided are methods of treating HIV-1 in a subject comprising administering an effective amount of the described HIV-1 vaccines to the subject in need thereof.
摘要翻译： 本文提供了使用EpiGraph方法确定的包含载体和群体遗传抗原的HIV-1疫苗。 还提供了包含载体，群体发生抗原和定制抗原的HIV-1疫苗。 还提供了设计和生产用于受试者的HIV-1疫苗的方法，包括使用EpiGraph方法产生的抗原氨基酸序列设计疫苗抗原以最优地覆盖地理区域内的多样性，并产生所述设计的疫苗抗原。 还提供了诱导效应记忆T细胞应答的方法，包括设计一个或多个EpiGraph氨基酸序列，产生包含一个或多个EpiGraph氨基酸序列的疫苗和载体，并将该疫苗给予受试者。 进一步提供了治疗受试者中的HIV-1的方法，其包括将有效量的所述HIV-1疫苗给予有需要的受试者。
-
公开(公告)号：EP3174864A2
公开(公告)日：2017-06-07
申请号：EP15827677.4
申请日：2015-07-31
申请人： Oregon Health & Science University , United States Department of Veterans Affairs , Organix Inc.
发明人： JANOWSKY, Aaron , MELTZER, Peter
IPC分类号： C07D239/96 , C07D495/04 , C07D401/06 , C07D403/06 , A61K31/517 , A61K31/519 , A61K31/506 , A61P25/00
CPC分类号： C07D401/06 , A61K31/506 , A61K31/517 , A61K31/519 , C07D401/14 , C07D405/14 , C07D409/14
摘要： Disclosed herein are compounds that bind to the vesicular monoamine transporter 2 (VMAT2), pharmaceutical compositions comprising those compounds, and methods of treatment using said compounds and pharmaceutical compositions.
摘要翻译： 本文公开了与泡状单胺转运蛋白2（VMAT2）结合的化合物，包含这些化合物的药物组合物，以及使用所述化合物和药物组合物治疗的方法。
-
60.发明公开METHOD FOR CONDUCTING CLINICAL TRIALS BASED ON SUBSTANTIALLY CONTINUOUS MONITORING OF OBJECTIVE QUALITY OF LIFE FUNCTIONS 审中-公开用于临床试验中的执行程序很大程度上连续监测质量生命功能的客观
公开(公告)号：EP3090371A1
公开(公告)日：2016-11-09
申请号：EP14828419.3
申请日：2014-12-23
发明人： KAYE, Jeffrey , AUSTIN, Daniel , DODGE, Hiroko
IPC分类号： G06F19/00
摘要： A system and method for conducting a clinical trial of a medical treatment of human patients. The system uses an array of sensors in the patient's home for substantially continuously monitoring one or more objective functions of the patient. The monitored objective functions of the patient are compared against a baseline set of data for the monitored objective functions for the patient or a set of patients. The comparison includes detecting a trend of deviation between the one or more monitored objective functions of the patient and the baseline set of data. The trend of deviation can be correlated with an application or nonapplication of the medical treatment to the patient.
-
-
-
-
-
-
-
-
-
搜索结果
201 条记录 (耗时 0.052 秒)
